Início › Leucemia Bifenotípica Aguda › Texas
Ensaios clínicos de Leucemia Bifenotípica Aguda em Texas
13 estudos para Leucemia Bifenotípica Aguda estão buscando participantes em locais em Texas.
Cidades em Texas
- Houston11 estudos
- Dallas6 estudos
- Fort Worth5 estudos
- Corpus Christi3 estudos
- El Paso3 estudos
- Austin3 estudos
- San Antonio3 estudos
Texto oficial do estudo (Inglês)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 1
Idades de 12 a 78 · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- e mais 7
RecrutandoFase 2
365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT03683433Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- e mais 12
RecrutandoFase 3
365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- e mais 10
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center, Dallas
- Cook Children's Medical Center, Fort Worth
RecrutandoFase 1
Idades de 1 a 30 · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT06177067Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
RecrutandoFase 2
Idades de 15 a 80 · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT02727803A Study of Revumenib and Mezigdomide in People With Leukemia
- MD Anderson Cancer Center (Data Collection Only), Houston
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 12 de jun. de 2026 · NCT04047641Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
RecrutandoFase 2
Idades de 18 a 65 · Todos os sexos · Atualizado em 20 de mai. de 2026 · NCT02115295The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
RecrutandoFase 1/2
Idades de 12 a 95 · Todos os sexos · Atualizado em 15 de abr. de 2026 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
RecrutandoFase 1
Idades de 1 a 21 · Todos os sexos · Atualizado em 6 de dez. de 2024 · NCT05476770Fonte: ClinicalTrials.gov, dados obtidos em 2 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.